Shopping Cart
- Remove All
Your shopping cart is currently empty
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $35 | In Stock | |
| 5 mg | $73 | In Stock | |
| 10 mg | $119 | In Stock | |
| 25 mg | $238 | In Stock | |
| 50 mg | $397 | In Stock | |
| 100 mg | $636 | In Stock | |
| 200 mg | $852 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $80 | In Stock |
| Description | PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer. |
| Targets&IC50 | EGFR tyrosine kinase:0.7 nM |
| In vitro | PKI-166 (0–0.5 μM; 1 hour) pretreatment suppresses EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 (0.03μ M; 6 days) increased the cytotoxicity mediated by gemcitabine.[1] |
| In vivo | PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) suppresses pancreatic cancer growth. |
| Molecular Weight | 330.38 |
| Formula | C20H18N4O |
| Cas No. | 187724-61-4 |
| Smiles | C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1 |
| Relative Density. | 1.324 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (83.24 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.